This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Hypoxia-inducible factor prolyl hydroxylase 2 (EGLN1; HIF-PH2; PHD2)	<p>Mouse studies suggest PHD2 inhibitors could help improve the efficacy of chemotherapies. In <i>Phd2</i>-deficient mice with murine lung or human melanoma tumors, cisplatin or doxorubicin decreased tumor growth and led to less chemotherapy-induced renal and cardiac damage compared with what was seen in wild-type mice with tumors treated with cisplatin or doxorubicin. Additional studies in those mice showed that <i>Phd2</i> deficiency induced a protective antioxidative response to chemotherapy in normal organs but not in tumors. Ongoing work includes investigating the effects of <i>Phd2</i> deficiency in mouse models of metastatic breast cancer.</p> <p>SciBX 5(34); doi:10.1038/scibx.2012.895 Published online Aug. 30, 2012</p>	<p>Patented by the Flanders Institute for Biotechnology (VIB); available for licensing or partnering Contact: Barbara Leyman, Flanders Institute for Biotechnology (VIB), Flanders, Belgium e-mail: barbara.leyman@vib.be</p>	<p>Leite de Oliveira, R. <i>et al. Cancer Cell</i>; published online Aug. 14, 2012; doi:10.1016/j.ccr.2012.06.028 Contact: Massimiliano Mazzone, Flanders Institute for Biotechnology (VIB), Flanders, Belgium e-mail: massimiliano.mazzone@vib-kuleuven.be</p>